2 december 2017: klik op de titel

Conclusions

After 5 years of adjuvant endocrine therapy, breast-cancer recurrences continued to occur steadily throughout the study period from 5 to 20 years. The risk of distant recurrence was strongly correlated with the original TN status, with risks ranging from 10 to 41%, depending on TN status and tumor grade. (Funded by Cancer Research UK and others.)


Gerelateerde artikelen
 

Gerelateerde artikelen

20-Year Risks of Breast-Cancer >> Algemeen: Aromataseremmers >> Alpelisib (Piqray) naast fulvestrant >> Arimidex - anastrozole, een >> Aromasin - exemestane geeft >> Avastin - bevacizumab faalt >> Chemo voor borstkanker met >> Clodronate bij borstkanker >> Everolimus (Afinitor) samen >> Fulvestrant - Faslodex geeft >>